The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•13 February 2026•

1 min read

Baxter International Misses Q4 EPS, Issues Weak FY26 Outlook; Stock Tumbles

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Baxter International (BAX) reported a significant net loss in Q4, with adjusted earnings per share (EPS) of $0.44, falling short of analysts' estimates of $0.54. This earnings miss occurred despite a notable 8% increase in worldwide net sales, reaching $2.97 billion. Adding to investor concerns, the medical products company provided a weak fiscal year 2026 outlook. It projected adjusted EPS for FY26 to be between $1.85 and $2.05, considerably below the Street's expectation of $2.25 per share. Following these announcements, Baxter's stock (BAX) experienced a sharp decline, tumbling 14.63% in pre-market trading. The disappointing Q4 results and subdued long-term guidance signal significant negative market sentiment for the company.